Pharmafile Logo
Pharmafocus logo
Advanced Search

hepatocellular carcinoma

Showing 4 posts of 4 posts found.

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer

July 30, 2025
Medical Communications, Research and Development AstraZeneca, NHS, National Institute for Health and Care Excellence, Oncology, dual immunotherapy, hepatocellular carcinoma, liver cancer

AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for its dual immunotherapy …

News
lilly_entrance_web

Lilly’s Cyramza approved in US for hepatocellular carcinoma sub-population

May 13, 2019
Sales and Marketing Eli Lilly, FDA, cyramza, hepatocellular carcinoma, pharma

Eli Lilly’s vascular endothelial growth factor (VEGF) receptor 2 antagonist Cyramza (ramucirumab) has received approval in the US as a …

News
msd

MSD’s Keytruda chalks up FDA approval in liver cancer

November 12, 2018
Sales and Marketing Cancer, FDA, US, hepatocellular carcinoma, keytruda, pharma

MSD’s blockbuster immunotherapy Keytruda has secured another FDA approval, this time for the treatment of hepatocellular carcinoma (HCC) in patients …

News
bayer_cross_2

FDA approves first new drug for liver cancer in decade

April 28, 2017
Medical Communications, Sales and Marketing Bayer, Stivarga, hepatocellular carcinoma, liver cancer

The FDA has announced that it has approved the first new treatment for hepatocellular carcinoma (HCC), a type of liver …

News
The Gateway to Local Adoption Series

Latest content

Molnlycke donates risk prediction patent to SKF’s digital patent platform

November 14, 2025

Study finds at-home brain stimulation therapies reduce depression relapse rate

November 14, 2025

Smurfit Westrock unveils new clinical packaging facility at Dublin Airport

November 13, 2025

EVerZom enters research and licensing agreement with GENFIT

November 13, 2025

University of Birmingham scientists develop new MRI contrast agent

November 12, 2025